Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed, refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018, 19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1.
Advertisement
Articles by Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed, refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018, 19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1.
Advertisement
Latest Updated Articles
- Study Summary: Once-Weekly Versus Twice-Weekly Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma: ARROW Interim Analysis
Published: October 24th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
2
Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen
3
Stronger Carer-Child Bonds Don’t Predict Later Mental Health
4
FDA to Remove Black Box Warnings From HRT, Debate Ensues
5
